CN Patent

CN109562084A — 蛋白酶体抑制剂和抗cd30抗体的组合

Assigned to Millennium Pharmaceuticals Inc · Expires 2019-04-02 · 7y expired

What this patent protects

本发明涉及用于治疗癌症的方法。特定地，本发明提供通过施用蛋白酶体抑制剂与抗CD30抗体的组合治疗癌症的方法。

USPTO Abstract

本发明涉及用于治疗癌症的方法。特定地，本发明提供通过施用蛋白酶体抑制剂与抗CD30抗体的组合治疗癌症的方法。

Drugs covered by this patent

ixazomib-citrate (IXAZOMIB CITRATE)

Patent Metadata

Patent number: CN109562084A
Jurisdiction: CN
Classification: —
Expires: 2019-04-02
Drug substance claim: No
Drug product claim: No
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.